Quantification & Classification of Inflammatory Cells in Uveitis Using OCT
Launched by OREGON HEALTH AND SCIENCE UNIVERSITY · Jul 2, 2025
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to look at inflammation inside the eye using a special imaging tool called optical coherence tomography (OCT). The goal is to find a clear and reliable method to count and classify the different cells and proteins involved in a type of eye inflammation called anterior uveitis, which can happen with several diseases like arthritis, infections, or other immune conditions. By using this imaging, doctors hope to better understand the inflammation without needing more invasive tests.
People who may be eligible include adults with active inflammation in the eye caused by conditions such as spondyloarthritis, juvenile arthritis, herpes virus, Birdshot chorioretinitis, Behcet disease, sarcoidosis, or other types of uveitis. The study also includes people with a common eye condition called posterior vitreous detachment, which causes floaters, as well as healthy individuals with no eye inflammation or surgery history. Participants will have eye scans using the OCT device and will need to attend all study visits. The study is currently recruiting adults aged 18 and older, and pregnant or breastfeeding women cannot take part. This research could help improve how eye inflammation is diagnosed and monitored in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Uveitis Group: Eyes with active intraocular inflammation and a clinical diagnose of spondyloarthritis/HLA-B27 associated anterior uveitis, Juvenile Idiopathic Arthritis (JIA) associated chronic anterior uveitis, Herpes Simplex Virus (HSV) anterior uveitis, Birdshot chorioretinitis, Behcet disease uveitis, sarcoidosis associated uveitis, uveitis of any additional type, or uveitis masquerade.
- • 2. Posterior Vitreous Detachment Group: Eyes with vitreous floaters and posterior vitreous detachment (PVD).
- • 3. Healthy/Control Group: Healthy eyes with no history of uveitis, PVD, or previous eye surgery.
- Exclusion Criteria:
- • 1. Inability to give informed consent.
- • 2. Inability to maintain stable fixation for OCT imaging.
- • 3. Inability to commit to required visits to complete the study.
- • 4. Pregnancy and breastfeeding.
About Oregon Health And Science University
Oregon Health and Science University (OHSU) is a leading academic medical center dedicated to advancing health through research, education, and patient care. As a prominent sponsor of clinical trials, OHSU leverages its extensive expertise in various medical fields to facilitate innovative research aimed at improving patient outcomes. The institution is committed to ethical standards and rigorous scientific methodologies, fostering collaborations that enhance the development of new therapies and interventions. With a focus on translating research discoveries into clinical practice, OHSU plays a pivotal role in shaping the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Portland, Oregon, United States
Patients applied
Trial Officials
Yan Li, PhD
Principal Investigator
Oregon Health and Science University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported